[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628480":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":37,"locations":45,"responsibleParty":66,"collaborators":25,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":25,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":25,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":25,"overallStatus":89,"whyStopped":25,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"RESnTEC, Institute of Research","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Enoxaparin Group","EXPERIMENTAL","Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery.",[13,14],"Drug: Enoxaparin","Other: Standard Management",{"label":16,"type":10,"description":17,"interventionNames":18},"Standard Management Group","Patients will continue with standard management alone.",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Enoxaparin","Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery",[9],null,{"type":6,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Standard Management",[9,16],[30,34],{"name":31,"affiliation":32,"role":33},"Maimoona Hafeez","Combined Military Hospital Quetta","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":32,"role":36},"Sidra Iqbal, FCPS","STUDY_DIRECTOR",[38,42],{"name":31,"role":39,"phone":40,"phoneExt":25,"email":41},"CONTACT","+923135495729","maimoonahafeez777@gmail.com",{"name":35,"role":39,"phone":43,"phoneExt":25,"email":44},"+923336391038","drsidraiqbal4@gmail.com",[46],{"facility":47,"status":25,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Combined Military Hospital","Quetta","Balochistan","80000","Pakistan","PK",{"type":54,"coordinates":55},"Point",[56,57],67.00141,30.18414,{"lat":57,"lon":56},[60,61,63,64],{"name":31,"role":39,"phone":40,"phoneExt":25,"email":41},{"name":62,"role":39,"phone":43,"phoneExt":25,"email":44},"Sidra Iqbal, PCPS",{"name":31,"role":33,"phone":25,"phoneExt":25,"email":25},{"name":65,"role":33,"phone":25,"phoneExt":25,"email":25},"Sidra Iqbal",{"type":67,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Muhammad Aamir Latif","Research Consultant","100628480","impact-of-enoxaparin-therapy-on-fetal-outcomes-in-intrauterine-growth-restriction-100628480",false,"NCT07462182","Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction","Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction With Oligohydramnios.","Inclusion Criteria:\n\n* Women aged 18-40 years\n* Singleton pregnancy\n* Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period)\n* Diagnosed with both IUGR and oligohydramnios\n* Willing to provide informed written consent\n\nExclusion Criteria:\n\n* Multiple gestation\n* Major fetal congenital anomalies\n* Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease)\n* Known coagulation disorders or contraindications to enoxaparin\n* Women already on anticoagulation therapy.","FEMALE","18 Years","40 Years",{"count":81,"type":82},108,"ESTIMATED","INTERVENTIONAL",[85],"NA","The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.",[88],"Intrauterine Growth Restriction","NOT_YET_RECRUITING","2026-03-04",{"date":92,"type":93},"2026-03-10","ACTUAL",{"date":95,"type":82},"2026-04-01",{"date":97,"type":82},"2026-09-30",{"name":68,"class":6},1]